Living-Donor Liver Transplant Follow-Up: A Single Center Experience

被引:1
|
作者
Laeeq, Syed Mudassir [1 ]
Hanif, Farina M. [1 ]
Luck, Nasir Hassan [1 ]
Mandhwani, Rajesh Kumar [1 ]
Iqbal, Jawed [1 ]
Mehdi, Syed Haider [2 ]
机构
[1] Sindh Inst Urol & Transplantat, Dept Hepatogastroenterol, Karachi 74200, Pakistan
[2] Sindh Inst Urol & Transplantat, Dept Hepatobiliary Surg, Karachi, Pakistan
关键词
Anti-viral agents; Diabetes mellitus; Dyslipidemia; HCV; Hypertension; HEPATITIS-C VIRUS; RISK-FACTORS; HCV; SOFOSBUVIR; INFECTION; RIBAVIRIN;
D O I
10.6002/ect.mesot2016.P122
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Liver transplant is a definite treatment of decompensated liver disease. Because of the shortage of livers from deceased donors, living-donor liver transplant is becoming more common. Here, we analyzed our clinical experience in the follow-up care of these patients. Materials and Methods: Liver transplant recipients seen at the Sindh Institute of Urology and Transplantation (Karachi, Pakistan) were included in this analysis. Baseline characteristics and follow-up events were recorded. Results: Our study population included 76 liver transplant patients registered at our clinic. Median age was 42 years, with 62 patients (81.6%) being males. The most common indication of transplant was hepatitis C virus-related cirrhosis (42 patients; 55%), followed by hepatitis B-hepatitis D virus coinfection (8 patients; 10.5%). Anastomotic biliary stricture developed in 16 patients (21.1%), which required biliary stenting. Biliary leak developed in 5 patients (6.6%), and renal cell carcinoma developed in 1 patient. Two recipients died due to hepatitis C virus-related fibrosing cholestasis hepatitis and pulmonary complications. Posttransplant diabetes mellitus developed in 36 (47.1%), hypertension in 17 (38.6%), and dyslipidemia in 19 patients (25%). Of 42 patients with hepatitis C virus infection, 26 were treated with pegylated interferon and ribavirin, of which 65.3% achieved sustained virologic response at 24 weeks. The other 16 patients received sofosbuvir combined with ribavirin for 24 weeks. A sustained virologic response at 12 weeks was achieved in 5 patients, with not yet determined results in the remaining patients. Seven patients were lost to follow-up. Conclusions: Hepatitis C-related cirrhosis was the most common indication for liver transplant, and infection recurrence was observed in our patients. Biliary anastomotic stricture formation was the most prevalent complication after transplant. As liver transplants are becoming more widely available for Pakistani patients at home and abroad, gastroenterologists and trainees in our country should be sensitized, educated, and skilled in the posttransplant care of these patients.
引用
收藏
页码:254 / 257
页数:4
相关论文
共 50 条
  • [41] Quality of life after adult living donor liver transplantation: A longitudinal prospective follow-up study
    Togashi, Junichi
    Sugawara, Yasuhiko
    Akamatsu, Nobuhisa
    Tamura, Sumihito
    Yamashiki, Noriyo
    Kaneko, Junichi
    Sakamoto, Yoshihiro
    Aoki, Taku
    Hasegawa, Kiyoshi
    Kokudo, Norihiro
    HEPATOLOGY RESEARCH, 2013, 43 (10) : 1052 - 1063
  • [42] Aspergillosis in Liver Transplant Recipients: A Single Center Experience
    Kim, Jong Man
    Kwon, Choon Hyuck David
    Joh, Jae-Won
    Song, Sanghyun
    Shin, Milljae
    Kim, Sung Joo
    Hong, Seung Heui
    Kim, Bok Nyeo
    Lee, Suk-Koo
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2010, 79 (04): : 267 - 274
  • [43] Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients
    Honda, Masaki
    Asonuma, Katsuhiro
    Hayashida, Shintaro
    Suda, Hiroko
    Ohya, Yuki
    Lee, Kwang-Jong
    Yamamoto, Hidekazu
    Takeichi, Takayuki
    Inomata, Yukihiro
    CLINICAL TRANSPLANTATION, 2013, 27 (03) : 426 - 435
  • [44] A comparative study of the use of selective digestive decontamination prophylaxis in living-donor liver transplant recipients
    Katchman, E.
    Marquez, M.
    Bazerbachi, F.
    Grant, D.
    Cattral, M.
    Low, C. Y.
    Renner, E.
    Humar, A.
    Selzner, M.
    Ghanekar, A.
    Rotstein, C.
    Husain, S.
    TRANSPLANT INFECTIOUS DISEASE, 2014, 16 (04) : 539 - 547
  • [45] Clinical Significance of the Cellular Pharmacodynamics of Tacrolimus in Living-Donor Liver Transplantation
    Mijiti, Abuduxukuer
    Matsuno, Naoto
    Takeuchi, Hironori
    Unezaki, Sakae
    Nagao, Takeshi
    Hirano, Toshihiko
    CELL TRANSPLANTATION, 2009, 18 (5-6) : 657 - 664
  • [46] Pseudomonas aeruginosa infection after living-donor liver transplantation in adults
    Hashimoto, M.
    Sugawara, Y.
    Tamura, S.
    Kaneko, J.
    Matsui, Y.
    Kokudo, N.
    Makuuchi, M.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (01) : 11 - 19
  • [47] Surgical complications after living and deceased donor liver transplant: The NSQIP transplant experience
    Amara, Dominic
    Parekh, Justin
    Sudan, Debra
    Elias, Nahel
    Foley, David P.
    Conzen, Kendra
    Grieco, Arielle
    Braun, Hillary J.
    Greenstein, Stuart
    Byrd, Claudia
    Ko, Clifford
    Hirose, Ryutaro
    CLINICAL TRANSPLANTATION, 2022, 36 (06)
  • [48] In-hospital mortality after adult living donor liver transplantation: single-center experience
    Gao, Wei
    Song, Jiu-Lin
    Feng, Ming-Ming
    Jiang, Li
    Yang, Jian
    Yang, Jia-Yin
    Yan, Lu-Nan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (05): : 8474 - 8481
  • [49] Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center
    Bin Hu, An
    Wu, Lin Wei
    Tai, Qiang
    Zhu, Xiao Feng
    He, Xiao Shun
    JOURNAL OF DIGESTIVE DISEASES, 2013, 14 (01) : 38 - 44
  • [50] A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant
    Lin, Kuo-Hua
    Chen, Yao-Li
    Lin, Ping-Yi
    Hsieh, Chia-En
    Ko, Chih-Jan
    Lin, Chia-Cheng
    Ming, Ying-Zi
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2017, 15 (01) : 65 - 68